+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Osteoporosis Drugs Market Size, Share, & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030- Product Image
Osteoporosis Drugs Market Size, Share, & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030- Product Image
New

Osteoporosis Drugs Market Size, Share, & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 5998844
Description Jump to:
The Osteoporosis Drugs Market was valued at USD 15.3 Billion in 2024, and is projected to reach USD 18.8 Billion by 2030, rising at a CAGR of 3.50%. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Osteoporosis Drugs Market Report Highlights

  • Branded drugs held the dominant share of the product segment in 2024. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
  • Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
  • In 2024, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
  • Asia-Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
  • The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Type
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Osteoporosis Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Osteoporosis Drugs Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Branded
4.4.1. Branded Market, 2018-2030 (USD Million)
4.5. Generics
4.5.1. Generics Market, 2018-2030 (USD Million)
Chapter 5. Osteoporosis Drugs Market: Type Business Analysis
5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Bisphosphonates
5.4.1. Bisphosphonates Market, 2018-2030 (USD Million)
5.5. Parathyroid Hormone Therapy
5.5.1. Parathyroid Hormone Therapy Market, 2018-2030 (USD Million)
5.6. Calcitonin
5.6.1. Calcitonin Market, 2018-2030 (USD Million)
5.7. Selective Estrogen Inhibitors Modulator (SERM)
5.7.1. Selective Estrogen Inhibitors Modulator (SERM) Market, 2018-2030 (USD Million)
5.8. Rank Ligand Inhibitors
5.8.1. Rank Ligand Inhibitors Market, 2018-2030 (USD Million)
5.9. Other Products
5.9.1. Other Products Market, 2018-2030 (USD Million)
Chapter 6. Osteoporosis Drugs Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2018-2030 (USD Million)
Chapter 7. Osteoporosis Drugs Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Osteoporosis Drugs Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Europe
7.5.1. Europe Osteoporosis Drugs Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Osteoporosis Drugs Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Osteoporosis Drugs Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8. MEA
7.8.1. MEA Osteoporosis Drugs Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Osteoporosis Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Amgen Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Eli Lilly and Company
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Merck & Co., Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Novartis AG
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Pfizer Inc.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. GSK plc
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Radius Health, Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. UCB S.A.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Teva Pharmaceutical Industries Ltd.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. F. Hoffmann-La Roche Ltd
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Osteoporosis Drugs Market, by Region, 2018-2030 (USD Million)
Table 4. Global Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 5. Global Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 6. Global Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 7. North America Osteoporosis Drugs Market, by Country, 2018-2030 (USD Million)
Table 8. North America Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 9. North America Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 10. North America Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 11. U.S. Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 12. U.S. Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 13. U.S. Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 14. Canada Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 15. Canada Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 16. Canada Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 17. Mexico Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 18. Mexico Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 19. Mexico Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 20. Europe Osteoporosis Drugs Market, by Country, 2018-2030 (USD Million)
Table 21. Europe Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 22. Europe Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 23. Europe Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 24. UK Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 25. UK Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 26. UK Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 27. Germany Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 28. Germany Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 29. Germany Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 30. France Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 31. France Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 32. France Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 33. Italy Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 34. Italy Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 35. Italy Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 36. Spain Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 37. Spain Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 38. Spain Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 39. Norway Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 40. Norway Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 41. Norway Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 42. Denmark Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 43. Denmark Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 44. Denmark Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 45. Sweden Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 46. Sweden Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 47. Sweden Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 48. Asia Pacific Osteoporosis Drugs Market, by Country, 2018-2030 (USD Million)
Table 49. Asia Pacific Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 50. Asia Pacific Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 51. Asia Pacific Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 52. Japan Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 53. Japan Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 54. Japan Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 55. China Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 56. China Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 57. China Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 58. India Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 59. India Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 60. India Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 61. Australia Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 62. Australia Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 63. Australia Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 64. South Korea Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 65. South Korea Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 66. South Korea Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 67. Thailand Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 68. Thailand Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 69. Thailand Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 70. Latin America Osteoporosis Drugs Market, by country, 2018-2030 (USD Million)
Table 71. Latin America Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 72. Latin America Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 73. Latin America Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 74. Brazil Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 75. Brazil Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 76. Brazil Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 77. Argentina Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 78. Argentina Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 79. Argentina Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 80. Middle East & Africa Osteoporosis Drugs Market, by Country, 2018-2030 (USD Million)
Table 81. Middle East & Africa Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 82. Middle East & Africa Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 83. Middle East & Africa Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 84. South Africa Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 85. South Africa Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 86. South Africa Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 87. Saudi Arabia Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 88. Saudi Arabia Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 89. Saudi Arabia Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 90. UAE Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 91. UAE Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 92. UAE Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
Table 93. Kuwait Osteoporosis Drugs Market, by Drug Class, 2018-2030 (USD Million)
Table 94. Kuwait Osteoporosis Drugs Market, by Type, 2018-2030 (USD Million)
Table 95. Kuwait Osteoporosis Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Osteoporosis drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation drug class
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Drug class, type and distribution channel outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Osteoporosis drugs market dynamics
Figure 12 Osteoporosis drugs market: Porter’s five forces analysis
Figure 13 Osteoporosis drugs market: PESTEL analysis
Figure 14 Osteoporosis drugs market: Drug class segment dashboard
Figure 15 Osteoporosis drugs market: Drug class market share analysis, 2024 & 2030
Figure 16 Branded market, 2018-2030 (USD Million)
Figure 17 Generics market, 2018-2030 (USD Million)
Figure 18 Osteoporosis drugs market: type segment dashboard
Figure 19 Osteoporosis drugs market: type market share analysis, 2024 & 2030
Figure 20 Bisphosphonates market, 2018-2030 (USD Million)
Figure 21 Parathyroid hormone therapy market, 2018-2030 (USD Million)
Figure 22 Calcitonin market, 2018-2030 (USD Million)
Figure 23 Selective estrogen inhibitors modulator (SERM) market, 2018-2030 (USD Million)
Figure 24 Rank ligand inhibitors market, 2018-2030 (USD Million)
Figure 25 Other products market, 2018-2030 (USD Million)
Figure 26 Osteoporosis drugs market: distribution channel segment dashboard
Figure 27 Osteoporosis drugs market: distribution channel market share analysis, 2024 & 2030
Figure 28 Hospital pharmacies market, 2018-2030 (USD Million)
Figure 29 Retail pharmacies market, 2018-2030 (USD Million)
Figure 30 Online pharmacies market, 2018-2030 (USD Million)
Figure 31 Osteoporosis drugs market revenue, by region
Figure 32 Regional marketplace: key takeaways
Figure 33 Regional marketplace: key takeaways
Figure 34 North America osteoporosis drugs market, 2018-2030 (USD Million)
Figure 35 U.S. Country dynamics
Figure 36 U.S. Osteoporosis drugs market, 2018-2030 (USD Million)
Figure 37 Canada country dynamics
Figure 38 Canada osteoporosis drugs market, 2018-2030 (USD Million)
Figure 39 Mexico country dynamics
Figure 40 Mexico osteoporosis drugs market, 2018-2030 (USD Million)
Figure 41 Europe osteoporosis drugs market, 2018-2030 (USD Million)
Figure 42 UK country dynamics
Figure 43 UK osteoporosis drugs market, 2018-2030 (USD Million)
Figure 44 Germany country dynamics
Figure 45 Germany osteoporosis drugs market, 2018-2030 (USD Million)
Figure 46 France country dynamics
Figure 47 France osteoporosis drugs market, 2018-2030 (USD Million)
Figure 48 Italy country dynamics
Figure 49 Italy osteoporosis drugs market, 2018-2030 (USD Million)
Figure 50 Spain country dynamics
Figure 51 Spain osteoporosis drugs market, 2018-2030 (USD Million)
Figure 52 Norway country dynamics
Figure 53 Norway osteoporosis drugs market, 2018-2030 (USD Million)
Figure 54 Sweden country dynamics
Figure 55 Sweden osteoporosis drugs market, 2018-2030 (USD Million)
Figure 56 Denmark country dynamics
Figure 57 Denmark osteoporosis drugs market, 2018-2030 (USD Million)
Figure 58 Asia pacific osteoporosis drugs market, 2018-2030 (USD Million)
Figure 59 Japan country dynamics
Figure 60 Japan osteoporosis drugs market, 2018-2030 (USD Million)
Figure 61 China country dynamics
Figure 62 China osteoporosis drugs market, 2018-2030 (USD Million)
Figure 63 India country dynamics
Figure 64 India osteoporosis drugs market, 2018-2030 (USD Million)
Figure 65 Australia country dynamics
Figure 66 Australia osteoporosis drugs market, 2018-2030 (USD Million)
Figure 67 South Korea country dynamics
Figure 68 South Korea osteoporosis drugs market, 2018-2030 (USD Million)
Figure 69 Thailand country dynamics
Figure 70 Thailand osteoporosis drugs market, 2018-2030 (USD Million)
Figure 71 Latin America osteoporosis drugs market, 2018-2030 (USD Million)
Figure 72 Brazil country dynamics
Figure 73 Brazil osteoporosis drugs market, 2018-2030 (USD Million)
Figure 74 Argentina country dynamics
Figure 75 Argentina osteoporosis drugs market, 2018-2030 (USD Million)
Figure 76 MEA osteoporosis drugs market, 2018-2030 (USD Million)
Figure 77 South Africa country dynamics
Figure 78 South Africa osteoporosis drugs market, 2018-2030 (USD Million)
Figure 79 Saudi Arabia country dynamics
Figure 80 Saudi Arabia osteoporosis drugs market, 2018-2030 (USD Million)
Figure 81 UAE country dynamics
Figure 82 UAE osteoporosis drugs market, 2018-2030 (USD Million)
Figure 83 Kuwait country dynamics
Figure 84 Kuwait osteoporosis drugs market, 2018-2030 (USD Million)
Figure 85 Company categorization
Figure 86 Company market position analysis
Figure 87 Strategic framework

Companies Mentioned

The companies profiled in this Osteoporosis Drugs market report include:
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GSK plc
  • Radius Health, Inc.
  • UCB S.A.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 15.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.8 Billion
Compound Annual Growth Rate3.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Postmenopausal Osteoporosis Treatment Market Size, Share & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Postmenopausal Osteoporosis Treatment Market Size, Share & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Hormone Therapy Market Report 2025 - Product Image

Hormone Therapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Osteoporosis Drugs Market by Drug Class, Route of Administration, Dosage Form, Distribution Channel, End User, Patient Gender - Global Forecast to 2030 - Product Image

Osteoporosis Drugs Market by Drug Class, Route of Administration, Dosage Form, Distribution Channel, End User, Patient Gender - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Bisphosphonates Market by Type, Administration Route, Dosage Form, Application, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Bisphosphonates Market by Type, Administration Route, Dosage Form, Application, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Osteoporosis Therapeutics - Global Strategic Business Report - Product Image

Osteoporosis Therapeutics - Global Strategic Business Report

  • Report
  • 340 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.